Literature DB >> 6795913

Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease.

B G Brown, M A Josephson, R B Petersen, C D Pierce, M Wong, H S Hecht, E Bolson, H T Dodge.   

Abstract

Twenty-four patients with coronary artery disease were studied during cardiac catheterization to determine the effects of sustained isometric handgrip exercise and intravenous dipyridamole and their combination on coronary and systemic hemodynamics and measured coronary luminal caliber. During 4 to 5 minutes of 25 percent maximal handgrip, blood pressure and heart rate increased 24 and 19 percent, respectively, coronary sinus flow increased to 1.7 x baseline value, and epicardial coronary arteries constricted to increase predicted flow resistance by 40 percent in 36 diseased arterial segments. After a 4 minute intravenous infusion of dipyridamole (0.56 mg/kg body weight), systemic pressure decreased 8 percent, heart rate increased 23 percent, coronary sinus flow increased to 2.4 x baseline value and coronary luminal caliber was unchanged. During isometric handgrip initiated 6 minutes after the infusion of dipyridamole, systemic pressure and heart rate increased to 14 and 31 percent, respectively, above control values, coronary sinus flow increased to 3.3 x baseline value (3.8 x baseline value in patients with normal anterior perfusion) and stenotic flow resistance increased by 36 percent. The response of coronary flow to the combined stresses was 68 percent greater than the response to dipyridamole alone (p less than 0.02); these flow levels exceed values previously reported for the human coronary circulation. Aminophylline plus nitroglycerin appears to assure patient safety.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6795913     DOI: 10.1016/0002-9149(81)90323-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Quantitative analysis of myocardial ischaemia on end-diastolic thallium 201 perfusion images.

Authors:  G A Hurwitz; M E Schwab; A C MacDonald; A A Driedger
Journal:  Eur J Nucl Med       Date:  1990

2.  Pharmacology of the coronary circulation.

Authors:  J C Sill
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

3.  A comparison of maximal exercise and dipyridamole thallium-201 planar gated scintigraphy.

Authors:  W Martin; A C Tweddel; G Main; I Hutton
Journal:  Eur J Nucl Med       Date:  1992

4.  New insights into coronary vasospasm.

Authors:  B G Brown; H T Dodge
Journal:  West J Med       Date:  1982-05

Review 5.  Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease.

Authors:  A S Iskandrian; M S Verani; J Heo
Journal:  J Nucl Cardiol       Date:  1994 Jan-Feb       Impact factor: 5.952

6.  Detection of coronary artery disease: comparison between technetium 99m-labeled sestamibi single-photon emission computed tomography and two-dimensional echocardiography with dipyridamole low-level exercise-stress.

Authors:  M J Cramer; E E van der Wall; W Jaarsma; J F Verzijlbergen; M G Niemeyer; A H Zwinderman; E K Pauwels
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

Review 7.  Pharmacology of coronary vasodilation: a brief review.

Authors:  C Orlandi
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

Review 8.  Assessment of myocardial perfusion by magnetic resonance imaging.

Authors:  J Crnac; M C Schmidt; P Theissen; U Sechtem
Journal:  Herz       Date:  1997-02       Impact factor: 1.443

Review 9.  Adenosine and the adaptation to exercise.

Authors:  R E Simpson; J W Phillis
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

10.  Relationship between regional myocardial blood flow and thallium-201 distribution in the presence of coronary artery stenosis and dipyridamole-induced vasodilation.

Authors:  A E Mays; F R Cobb
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.